Skip to content

Study on Specific Antibody Avidity and Cellular Immune Responses Induced by Different Doses of Domestic Bivalent HPV16/18 Vaccine in Young Chinese Women

Study on Specific Antibody Avidity and Cellular Immune Responses Induced by Different Doses of Domestic Bivalent HPV16/18 Vaccine in Young Chinese Women

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105458
Enrollment
Unknown
Registered
2025-07-03
Start date
2023-10-21
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

Single-dose domestic HPV vaccine group:NA
Multi-dose domestic HPV vaccine group:NA
single-dose imported HPV vaccine group:NA

Sponsors

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
9 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Permanent residents in study sites (2) Females (3) The age of enrollment is 9-45 years old (4) The study participants and their parents/legal guardians (applicable to participants aged 9-18 years) are able to understand the requirements mentioned in the study protocol (5) Written informed consent obtained from the study participants and their parents/legal guardians (applicable to participants aged 9-18 years)

Exclusion criteria

Exclusion criteria: Refusal to participate in this study

Design outcomes

Primary

MeasureTime frame
Seropositivity rate;

Secondary

MeasureTime frame
Antibody Titer;Antibody concentration;Memory T cell response levels;Memory B cell response levels;

Countries

China

Contacts

Public ContactFanghui Zhao

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

zhaofangh@cicams.ac.cn+86 10 8778 8977

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026